AMC Partnering Up at Quintiles
AMC Partnering Up at Quintiles
Applied Clinical Trials recently spoke with Oren Cohen, MD, Chief Medical and Scientific Officer for Quintiles Transnational about the CRO’s relationship with Academic Medical Centers. This interview was conducted as part of a larger article in development for our February Special Report: AMCs and Clinical Trials.
According to Cohen, Quintiles has increased its partnerships with AMCs, as well as independent medical centers, in just the past two years. “We have to wait some time before we can judge how successful these relationships are,” said Cohen. “There is the natural of life cycle of studies, which could be up to eight years to see how it goes.”
However, for Quintiles, Cohen believes these partnerships are going well. By concentrating the portfolio of studies “under one roof,” Quintiles has the following benefits:
-Faster study start-up time
-More predictable enrollment
-Access to thought-leaders
-High-concentration of efficiencies (i.e., with monitoring)
“Partnerships that make sense for efficiency are good for everybody,” said Cohen. “Times change and everybody is under more economic pressure, AMCs, CROs…airlines and the auto industry.”
Look for our full report in our February issue.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
